Biomark Diagnostics
Financials
Estimates*
| CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | - | <1m | <1m | <1m |
| % growth | - | - | 72 % | - | - | 249 % | 6 % |
| EBITDA | (<1m) | (<1m) | (1.2m) | (1.1m) | (1.2m) | (1.3m) | (<1m) |
| % EBITDA margin | (473 %) | (355 %) | (452 %) | - | (2785 %) | (877 %) | (563 %) |
| Profit | (<1m) | (<1m) | (1.2m) | (1.1m) | (1.5m) | (1.8m) | (1.4m) |
| % profit margin | (473 %) | (355 %) | (462 %) | - | (3309 %) | (1200 %) | (875 %) |
| EV / revenue | 20.5x | 21.5x | 48.6x | - | 392.9x | 110.8x | 160.7x |
| EV / EBITDA | -4.3x | -6.0x | -10.8x | -27.9x | -14.1x | -12.6x | -28.5x |
| R&D budget | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| R&D % of revenue | 38 % | 37 % | 16 % | - | 1133 % | 356 % | 399 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
CAD830k | Grant | ||
CAD170k | Grant | ||
* | N/A | CAD235k | Post IPO Debt |
* | N/A | CAD1.3m | Private Placement VC |
* | N/A | $1.9m | Private Placement VC |
* | $290k | Grant | |
| Total Funding | €3.5m | ||
Related Content
Recent News about Biomark Diagnostics
EditBioMark Diagnostics is a pioneering company in the field of early-stage cancer detection. Utilizing advanced liquid biopsy technology, BioMark offers innovative solutions for the early detection, monitoring, and screening of hard-to-detect cancers. The company's technology focuses on identifying specific biomarkers in blood samples, which can indicate the presence of cancer at an early stage. This approach significantly improves patient outcomes by enabling earlier intervention and treatment.
BioMark serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. Operating in the biotechnology and diagnostics market, the company leverages its proprietary technology to offer a unique value proposition in the early cancer detection space. BioMark's business model is centered around the commercialization of its diagnostic tools, generating revenue through the sale of its technology and related services.
The company is supported by a global team of scientists, engineers, and medical professionals, all dedicated to advancing cancer diagnostics. BioMark's innovative approach and commitment to improving patient outcomes position it as a leader in the biotechnology industry.
Keywords: liquid biopsy, early cancer detection, biomarkers, diagnostics, biotechnology, patient outcomes, cancer screening, healthcare innovation, medical technology, metabolomics.